Literature DB >> 25800758

Polypharmacy: geriatric oncology evaluation should become mainstream.

Stuart M Lichtman1.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 25800758     DOI： 10.1200/JCO.2014.60.3548

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

Review 1.  A Comprehensive Look at Polypharmacy and Medication Screening Tools for the Older Cancer Patient.

Authors:  Andrew M Whitman; Kathlene A DeGregory; Amy L Morris; Erika E Ramsdale
Journal:  Oncologist       Date:  2016-05-05

Review 2.  From Assessment to Implementation and Beyond in Cancer and Aging Research.

Authors:  Stuart M Lichtman; Harvey J Cohen; Hyman Muss; William P Tew; Beatriz Korc-Grodzicki
Journal:  J Clin Oncol       Date:  2021-05-27       Impact factor: 50.717

Review 3.  Interventions to improve the appropriate use of polypharmacy for older people.

Authors:  Audrey Rankin; Cathal A Cadogan; Susan M Patterson; Ngaire Kerse; Chris R Cardwell; Marie C Bradley; Cristin Ryan; Carmel Hughes
Journal:  Cochrane Database Syst Rev       Date:  2018-09-03

4.  Geriatric Research Policy: Japan Clinical Oncology Group (JCOG) policy.

Authors:  Tomonori Mizutani; Kenichi Nakamura; Haruhiko Fukuda; Asao Ogawa; Tetsuya Hamaguchi; Fumio Nagashima
Journal:  Jpn J Clin Oncol       Date:  2019-10-01       Impact factor: 3.019
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.